Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E24.35 EPS (ttm)2.32 Insider Own0.10% Shs Outstand1.63B Perf Week-0.48%
Market Cap92.33B Forward P/E15.26 EPS next Y3.71 Insider Trans0.29% Shs Float1.63B Perf Month5.41%
Income3.82B PEG2.24 EPS next Q0.86 Inst Own73.30% Short Float0.90% Perf Quarter9.55%
Sales21.04B P/S4.39 EPS this Y-10.90% Inst Trans0.19% Short Ratio1.98 Perf Half Y-8.56%
Book/sh7.83 P/B7.22 EPS next Y8.68% ROA2.70% Target Price57.53 Perf Year2.67%
Cash/sh4.15 P/C13.64 EPS next 5Y10.85% ROE6.80% 52W Range49.96 - 70.05 Perf YTD-7.73%
Dividend1.60 P/FCF45.91 EPS past 5Y15.30% ROI20.20% 52W High-19.11% Beta1.00
Dividend %2.83% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin70.40% 52W Low13.42% ATR0.82
Employees23700 Current Ratio1.50 Sales Q/Q5.40% Oper. Margin23.70% RSI (14)61.80 Volatility1.11% 1.45%
OptionableYes Debt/Eq0.60 EPS Q/Q-3.80% Profit Margin4.40% Rel Volume0.43 Prev Close56.54
ShortableYes LT Debt/Eq0.45 EarningsJul 26 BMO Payout280.50% Avg Volume7.43M Price56.67
Recom2.60 SMA201.58% SMA505.05% SMA200-5.47% Volume2,280,197 Change0.22%
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Jul-20-18 11:26AM  [$$] IFM Therapeutics Launches Subsidiary With $31 Million Series A The Wall Street Journal
Jul-19-18 11:51AM  Value investors Nygren's stock buys: Hilton, Gartner and ... CNBC Videos
07:00AM  Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors Business Wire
Jul-13-18 08:50AM  Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks
Jul-12-18 06:03PM  3 Pharma Stocks Goldman Sachs Sees as Buys
09:21AM  Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer Zacks
Jul-11-18 03:11PM  Russian Drugmaker Granted License to Produce Celgene Copycat Fortune
07:05AM  Moffitt licensing deal could provide new approach for some cancer patients American City Business Journals
06:59AM  Bristol-Myers Squibbs Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and... Business Wire
Jul-09-18 05:37PM  Could P&G bid for Bristol-Myers Squibb unit? American City Business Journals
01:26PM  Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma CNW Group
07:10AM  Wired News - The European Commission Approves Expanded Indication for Bristol-Myers Squibb's Sprycel ACCESSWIRE
Jul-08-18 07:16PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Jul-06-18 07:41AM  Bristol-Myers' Sprycel Gets EC Approval for Label Expansion Zacks
Jul-05-18 12:03PM  Pfizer's Stock Ready for a 10% Rebound Investopedia
11:46AM  Go Long Pfizer Stock Its an Easy Pill to Swallow InvestorPlace
06:59AM  European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Business Wire
Jul-03-18 06:01AM  The 5 Biggest Blockbuster Drugs of 2024, and the Companies Poised to Profit From Them Motley Fool
Jun-29-18 07:54AM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma Business Wire
Jun-26-18 02:16PM  Bristol-Myers Stock May Rebound 9% Short Term Investopedia
07:30AM  Wired News - FDA Accepts Bristol-Myers Squibbs Application for Opdivo Plus Low-Dose Yervoy for First-Line Non-Small Cell Lung Cancer Treatment ACCESSWIRE
06:00AM  13 Companies With Attractive, Low-Risk Dividends Morningstar
Jun-22-18 04:56PM  Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA Zacks
09:52AM  Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI Zacks
08:51AM  Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap Benzinga
Jun-21-18 04:15PM  U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden 10 mut/Mb Business Wire
08:49AM  What You Must Know About Bristol-Myers Squibb Companys (NYSE:BMY) 7.31% ROE Simply Wall St.
07:28AM  Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities ACCESSWIRE
Jun-20-18 09:02AM  NYSE Pharma And Biotech Dividend Stock Picks Simply Wall St.
06:59AM  Dallas Cowboys Quarterback Dak Prescott, Modern Family Star Eric Stonestreet and Actress Tia Mowry Call on Americans to Rise Up Against Cancer Through Ready. Raise. Rise. Business Wire
Jun-18-18 06:23PM  Bristol-Myers Posts Data on Empliciti, China Approves Opdivo Zacks
03:00PM  Eight Stocks That Are Poised to Change Direction
06:00AM  5 Drug Stocks With Fat Payouts Investopedia
Jun-17-18 06:30AM  Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma Business Wire
Jun-15-18 02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool
08:32AM  China National Drug Administration Approves Countrys First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) Business Wire
Jun-14-18 04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
Jun-13-18 06:00AM  Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) Business Wire
Jun-12-18 05:32PM  Does Bristol-Myers Squibb Companys (NYSE:BMY) PE Ratio Signal A Selling Opportunity? Simply Wall St.
Jun-11-18 04:45PM  Bristol-Myers Squibb to Take Part in Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
09:29AM  Fred Hutch leases iconic Lake Union Steam Plant facility American City Business Journals
09:08AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie Zacks
Jun-08-18 10:27AM  Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant Zacks
Jun-07-18 09:09PM  Why Nektar Therapeutics Stock Stumbled 11.8% Today Motley Fool
06:59AM  Bristol-Myers Squibb to Announce Results for Second Quarter 2018 on July 26 Business Wire
Jun-06-18 04:15PM  Here's Why Nektar Therapeutics Jumped as Much as 17% Today Motley Fool
08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
Jun-05-18 11:00AM  Nektar Therapeutics Stock Is a Buy After a Major Market Misread InvestorPlace
08:42AM  Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study Zacks
08:13AM  Do Nektars disappointing clinical trial results invalidate $2 billion Bristol-Myers deal? MarketWatch
06:08AM  Bristol-Myers (BMY) Reports Data from CheckMate-214 Study Zacks
Jun-04-18 05:14PM  Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug
04:40PM  Is Nektar Therapeutics Stock a Bargain Now? Motley Fool
03:56PM  $15 billion biotech stock loses more than 40% of its value after skin cancer drug study falls short CNBC
03:32PM  Merck emerges as key winner at ASCO conference CNBC Videos
02:54PM  US STOCKS-Technology rally helps Wall Street push higher Reuters
02:30PM  Why Bristol-Myers Squibb Company Shares Are Down Today InvestorPlace
01:49PM  [$$] Nektar's 39% Drop: A New Record for a Volatile Stock
01:45PM  Why Nektar Therapeutics Shares Are Plunging Today InvestorPlace
09:39AM  Nektar shares drop 35% on 'underwhelming' cancer trial data MarketWatch
09:00AM  Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma Business Wire
08:15AM  Bristol-Myers Squibb CEO: We are conducting important stu... CNBC Videos
06:59AM  Opdivo Plus Chemotherapy Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Patients with PD-L1 <1%, in CheckMate -227 Study to Be Presented at ASCO 2018 Business Wire
05:00AM  Nektar Plummets on Concerns Over Cancer-Drug Trial Results Bloomberg
Jun-03-18 09:49PM  Mixed results for Bristol/Nektar combination in cancer trial Reuters
Jun-02-18 07:53PM  Nektar And Bristol Hurtle Forward With Experimental Cancer Drug Forbes
06:10PM  Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018 PR Newswire
Jun-01-18 06:50PM  U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma Business Wire
06:59AM  Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study Business Wire
May-31-18 01:42PM  ASCO Conference Preview: Here's What Biotech Investors Need to Watch Motley Fool
May-30-18 09:17AM  5 Best-Selling Orphan Drugs in the U.S. Motley Fool
May-28-18 05:00AM  Why Is Bristol-Myers Squibb (BMY) Up 1.3% Since Its Last Earnings Report? Zacks
May-24-18 06:59AM  Bristol-Myers Squibb to Hold Investor Event to Discuss ASCO Highlights Business Wire
May-23-18 05:56PM  Why Big Pharma is finally discovering the Bay Area American City Business Journals
May-22-18 11:56PM  Warren Buffett Loves TEVA Stock and You Should Too InvestorPlace
May-21-18 07:15AM  Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space ACCESSWIRE
May-16-18 05:07PM  Bristol-Myers Squibb Highlights Breadth of Immuno-OncologyBased Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018 Business Wire
07:09AM  Jim Cramer Advises His Viewers On Consolidated Edison, L Brands And More Benzinga
May-15-18 06:59PM  Cramer's lightning round: Take a pass on Bristol-Myers Sq... CNBC Videos
06:47PM  Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now CNBC
02:28PM  Nektar Therapeutics Stock Is Risky But Offers Big Reward InvestorPlace
06:59AM  Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference Business Wire
May-10-18 05:50PM  Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs American City Business Journals
02:58PM  MARKETS: Biotech and pharma stocks could be the key to the market bull case Yahoo Finance Video
May-09-18 11:20AM  Why Bristol-Myers Squibb Stock Crashed in April Motley Fool
May-07-18 02:32AM  Roche's Tecentriq combo wins fast FDA review in race to catch rivals Reuters
May-04-18 05:35PM  As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soars American City Business Journals
02:14PM  Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote Benzinga
11:55AM  Q1 Earnings Drag Pharma ETFs Down Zacks
08:00AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
May-03-18 10:24AM  What's in Store for Celldex (CLDX) This Earnings Season? Zacks
08:38AM  European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire
May-02-18 09:31AM  The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda Zacks
08:30AM  Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement Business Wire
07:30AM  Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers Forbes
May-01-18 04:39PM  How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer American City Business Journals
04:11PM  Dow Jones' Merck Slides On Mixed First Quarter As Keytruda Sales Pop Investor's Business Daily
03:41PM  Stephanie Link adds to Zimmer Biomet after earnings & bets on one gambling giant CNBC
11:05AM  Top Stock Reports for Amazon, Bristol-Myers & Time Warner Zacks
07:21AM  Sales of cancer drug Keytruda power Merck to a first-quarter earnings beat CNBC
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM